Skip Navigation



European Heart Journal Advance Access published online on February 13, 2007
European Heart Journal, doi:10.1093/eurheartj/ehl490
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/6/719    most recent
ehl490v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brunner-La Rocca, H.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunner-La Rocca, H.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET){dagger}

Hans-Peter Brunner-La Rocca, Christoph Kaiser, Matthias Pfisterer on behalf of the BASKET Investigators*

Division of Cardiology, University Hospital Basel, CH 4031, Switzerland

Received 10 October 2006; revised 27 December 2006; accepted 4 January 2007.

* Corresponding author. Tel: +41 61 265 25 25/52 14; fax: +41 61 265 45 98. E-mail address: pfisterer{at}email.ch

AIMS: It is unknown which patients benefit most from drug-eluting stents (DES) against bare-metal stents (BMS) in a long-term clinical outcome.

METHODS AND RESULTS: To address this question, data from 826 consecutive patients with angioplasty, randomized 2:1 to DES vs. BMS, with an 18-month follow-up for cardiac death/myocardial infarction (MI) and non-MI-related target-vessel revascularization (TVR) were analysed for interactions between stent type and patient/vessel characteristics predicting events. Rates of 18-month TVRs were lower with DES vs. BMS use (7.5 vs. 11.6%, P = 0.05), but similar for both stents regarding cardiac death/MI (DES, 8.4%; BMS, 7.5%; P = 0.70). Significant interactions between stent type and two multivariable event predictors were identified: small stents (<3.0 mm) and bypass graft stenting. In these patient groups together (n = 268, 32%), DES reduced non-MI-related TVR (HR = 0.44; P = 0.02) and cardiac death/MI (HR = 0.44; P = 0.04), whereas in the other 558 patients (68%) TVR rate was similar (HR = 0.75; P = 0.38) and cardiac death/MI rate increased after DES (HR = 2.07; P = 0.05).

CONCLUSION: Patients with angioplasty of small vessels or bypass grafts seem to benefit from DES use, in long-term outcome, in contrast to patients with large native vessel stenting where there might even be late harm. Still, this hypothesis needs to be tested prospectively.

Key Words: Angioplasty • Coronary disease • Outcome • Stents • Stent thrombosis

{dagger} BASKET/BASKET-LATE Hospitals and Investigators: Kaiser et al. (2005)8


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
A. Menozzi, E. Solinas, P. Ortolani, A. Repetto, F. Saia, G. Piovaccari, A. Manari, E. Magagnini, L. Vignali, E. Bonizzoni, et al.
Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study
Eur. Heart J., September 1, 2009; 30(17): 2095 - 2101.
[Abstract] [Full Text] [PDF]

Home page
 Circ Cardiovasc IntervHome page
Effect of Length and Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes
Circ Cardiovasc Interv, February 1, 2009; 2(1): 35 - 42.


Home page
 Eur Heart JHome page
M. Pfisterer, H. P. Brunner-La Rocca, P. Rickenbacher, P. Hunziker, C. Mueller, F. Nietlispach, G. Leibundgut, F. Bader, C. Kaiser, and for the BASKET Investigators
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET
Eur. Heart J., January 1, 2009; 30(1): 16 - 24.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M. E Pfisterer
Commentary on drug-eluting stents: to use or not to use--that is the question!
Heart, December 1, 2008; 94(12): 1648 - 1650.
[Full Text] [PDF]

Home page
 Ther Adv Cardiovasc DisHome page
F. Saia, A. Marzocchi, and A. Branzi
Review: The safety of drug-eluting stents
Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 43 - 52.
[Abstract] [PDF]

Home page
 CirculationHome page
S. Windecker and B. Meier
Late Coronary Stent Thrombosis
Circulation, October 23, 2007; 116(17): 1952 - 1965.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Agostoni, P. Vermeersch, S. Verheye, P. Van den Heuvel, C. Convens, F. Van den Branden, and G. Van Langenhove
Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J., August 1, 2007; 28(15): 1912 - 1913.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
B. Meier
(Active) stents are no panacea, a deja-vu
Eur. Heart J., March 2, 2007; 28(6): 653 - 654.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.